Lipid/Metabolic

Oct 6, 2008 17:00 EDT

Is there a role for statin therapy in heart failure? Join Drs John JV McMurray , Michel White, Jonathan Howlett, and Robert McKelvie as they discuss new data from the GISSI-HF and CORONA trials.

Lipid/Metabolic

Examining the effects of CB1 blockade on CAD with IVUS: STRADIVARIUS results

5 COMMENTS - Jun 27, 2008 10:49 EDT

Ongoing interest exists in developing new pharmacologic approaches to address obesity and its sequelae of metabolic risk. Can intravascular ultrasound help us determine if we are on the right track to decreasing atherosclerotic progression with drug therapies? Join us for an insightful interview with Dr. Nissen on the STRADIVARIUS results, the benefits of IVUS and ongoing research examining CB1 blockade and its potential ability to decrease atherosclerotic progression by impacting more than just LDL reduction.

Lipid/Metabolic

Dyslipidemia and type 2 diabetes: Translating clinical trial data into improving outcomes

14 COMMENTS - Jun 9, 2008 17:47 EDT

Join Drs Frank Sacks, Peter Jones and Theodore Mazzone as they discuss how the results of new clinical trials will affect the treatment of mixed dyslipidemia and reduce cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

Medical Crossfire: Hot Topics in Hypercholesterolemia: Impact of Recent Clinical Trial Data on Clinical Practice

May 30, 2008 15:55 EDT

Review data from recent trials on lipid-lowering agents, and evaluate this data within current lipid-lowering strategies to develop an evidence-based strategy for reducing CV risk in patients with hypercholesterolemia. Join Drs Davidson, Jones, and Radar.

Lipid/Metabolic

The future of cardiometabolic risk: What lies ahead for your patients?

May 27, 2008 09:32 EDT

Drs Eckel, Libby, Musselman, Nesto and Nissen review evidence concerning the role of the endocannabinoid system (ECS) in cardiometabolic risk and its management. They also analyze emerging therapies for cardiometabolic risk and obesity, including compounds directed at the ECS.

Lipid/Metabolic

Low HDL-C: What do you do in your practice?

15 COMMENTS - Apr 24, 2008 10:47 EDT

Which is the most important CV risk factor in controlling the progression of CVD? Click to take the survey and compare answers. The results will help us create future CME programming. This activity is part of an independent educational grant from Abbott.

Lipid/Metabolic

Using imaging to measure the impact of statin therapy on atherosclerotic plaque regression

Apr 15, 2008 15:00 EDT

Join Drs Steven Nissen, Eva Lonn, Subodh Verma, and James Stone as they discuss how imaging can evaluate the impact of treatment of atherosclerotic cardiovascular disease and provide a valuable surrogate end point for clinical trials.

Lipid/Metabolic

Mixed dyslipidemia: Attenuating risk... treatment beyond LDL

50 COMMENTS - Mar 19, 2008 12:51 EDT

Join Drs Christie Ballantyne and Michael Davidson as they discuss the barriers to reaching target levels of all three key lipid components - LDL-C, HDL-C and triglycerides in the reduction of cardiovascular risk.

Lipid/Metabolic

Statins and the vasculature: benefits beyond the lipid profile

Dec 27, 2007 10:30 EST

Lipid/Metabolic

Cardiometabolic risk in the spotlight: Which therapies should take center stage?

1 COMMENT - Dec 18, 2007 13:39 EST

Drs Smith, Rader, Nesto, Plutzky, Nemeroff, and Pagotto explore the interrelated role of cardiometabolic risk factors and analyze the mechanism of action and evidence for the effectiveness of cannabinoid receptor type 1 (CB1) blockade in CVD.

Dyslipidemia

Statins in the treatment of heart failure: What's new? - A Canadian perspective

Dec 10, 2007 11:00 EST

Whats new on statins in heart failure? Drs Nissen, Howlett, Roberts and Welsh discuss interesting late breaking results from the CORONA study on rosuvastatin in heart failure and put them in context with a prior subgroup analysis from TNT.

Lipid/Metabolic

Taming abdominal obesity: Preventing the attack of CVD and diabetes

Nov 21, 2007 10:45 EST

Recent studies reveal that weight loss can directly decrease CV mortality and increase longevity. How do clinicians determine the right combination of therapies to promote weight loss and decrease risk factors associated with CVD and diabetes? Join our international faculty for this stimulating discussion.

Lipid/Metabolic

Abdominal obesity: The perfect storm of CVD and diabetes

4 COMMENTS - Nov 16, 2007 15:00 EST

Should clinicians intervene for "overweight" patients or just for the "obese" regarding risk of CVD and diabetes? Does abdominal obesity create the perfect storm for catastrophic events? Join Professors Deanfield and Steg as they examine these questions through case study review.

Lipid/Metabolic

EASD 2007: Keys to prevention in diabetes and CV risk

Oct 17, 2007 15:30 EDT

The incidence of type 2 diabetes worldwide has increased from 30 million to 246 million over the last two decades, and continues to escalate. Some studies have revealed that approximately 80% of people with diabetes die of cardiovascular complications. This program will capitalize on cardiovascular risk, glycemic control and genetics influencing prevention and treatment in diabetes.

Cardiometabolic risk

Test your knowledge on risk assessment and intervention for patients with dysglycemia

Aug 30, 2007 15:40 EDT

Did you know that people with prediabetes have a 1.5-fold increased risk of CV disease compared to individuals with normal glucose levels? Are you aware that the presence of diabetes alone can make one 5 times more likely to die from heart disease? Consider the likelihood if other risk factors are present. Are you doing all that you can to minimize your patients CV risk? Test your knowledge regarding risk assessment and intervention for patients with dysglycemia.

Lipid/Metabolic

Charting the course of CV risk in diabetes: Case study analysis

Jun 28, 2007 16:35 EDT

People with prediabetes have a 1.5-fold increased risk of cardiovascular disease compared to those with normal glucose levels. Once diabetes develops, CV complications frequently occur at an earlier age, resulting in premature death. Are we overlooking "warning signals" that CV injury is imminent? Join Drs Nesto and Hollander for this intriguing case study review.

Lipid/Metabolic

Running the race against CV risk in diabetes: Are we doing enough?

3 COMMENTS - Jun 27, 2007 09:00 EDT

Are you aware that people with diabetes who have no other cardiovascular risk factors may be as much as 5 times more likely to die from heart disease than non-diabetics? We target blood pressure, glucose and LDL levels... but is that enough? Should we focus more on weight loss? Join Drs Nesto, Hollander and Leiter as they explore other avenues for targeting CV risk.

Cardiometabolic risk

How do I manage cardiometabolic risk?

32 COMMENTS - Apr 18, 2007 13:38 EDT

CV risk factor assessment: Intra-abdominal adiposity and global cardiometabolic risk. This questionnaire is designed to measure your perceptions and clinical practices in comparison to your peers regarding cardiovascular disease risk assessment. The questions target intra-abdominal adiposity, global risk factors and the fascinating synergy between them.

Lipid/Metabolic

Juggling multiple risk factors to target global cardiometabolic risk

3 COMMENTS - Apr 3, 2007 13:39 EDT

With over 300 million obese individuals worldwide, the incidence of CVD and type 2 diabetes continue to escalate. The clinician is perplexed with managing multiple risk factors and juggling many treatment regimens. The potential for CB1 blockade represents a novel approach to addressing multiple synergistic risks by targeting the primary culprit — abdominal obesity.

Lipid/Metabolic

CB1 blockade and type 2 diabetes: The SERENADE study

Jan 25, 2007 13:56 EST

Diabetes affects approximately 194 million individuals worldwide. A large majority of these cases is due to type 2 diabetes and is linked to patients being overweight or obese. Reducing weight and controlling glucose in diabetic patients is important in order to minimize the risk of heart disease and other disabling complications. The SERENADE study examined the benefit of using CB1 blockade in type 2 diabetes to tackle cardiometabolic risk.

Cardiometabolic risk

Knowledge of cardiometabolic risk: How do you measure up?

2 COMMENTS - Dec 20, 2006 10:32 EST

Despite lifestyle changes and current drug therapies, obesity and cardiometabolic risk remain persistent treatment challenges. Are you up to date on emerging pharmacological options? Test your knowledge against your peers regarding the use of CB1 blockade.

Lipid/Metabolic

Treating patients with CB1 blockade: The United Kingdom experience

4 COMMENTS - Dec 19, 2006 11:51 EST

With 23% of the population worldwide now obese, the risks of developing CV disease and type 2 diabetes are escalating. Lifestyle changes and current pharmacological interventions are having limited success. Explore case studies of CB1 blockade as part of the treatment regimen in countries where approved.

Lipid/Metabolic

CB1 blockade: Who's the ideal patient?

Nov 23, 2006 11:50 EST

In recent years, healthcare providers have become more aware of the risks of CVD and diabetes associated with abdominal obesity. What if the patient is not obese but simply overweight? How do we best assess the risk? What do we do when lifestyle changes and conventional pharmacological treatments are not successful? Evidence supports that cannabinoid-1 receptor (CB1) blockade therapy could be a promising alternative. If CB1 blockade becomes available in the United States, who will be the ideal candidate? Join our faculty as they explore these thought-provoking questions.

Lipid/Metabolic

Tackling abdominal obesity and cardiovascular risk around the world

Oct 12, 2006 10:32 EDT

Obesity is a growing epidemic around the world, with over 300 million obese individuals worldwide. The presence of abdominal obesity, which is easily determined by measuring waist circumference, has been identified as a contributing factor to cardiovascular risk. Ethnic and gender differences related to this disorder exist around the globe. This program will highlight the magnitude of the problem, explore gender and ethnic differences, and discuss strategies for managing the care of obese patients. Get the Canadian perspective on abdominal obesity and cardiovascular risk from Drs Abramson, Genest, and Lonn.

Lipid/Metabolic

Highlights from EASD 2006: Targeting CV risk in dysglycemic patients

Oct 6, 2006 15:26 EDT

The incidence of diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. One contributing factor to the escalating incidence is the global epidemic of abdominal obesity. Modern lifestyles and dietary habits are contributing to an increase in diabetes with a consequent rise in inter-related cardiometabolic risk factors. This program will review recent research findings related to the relationship between cardiometabolic risk factors and diabetes, with an emphasis on future trends for management of the patient with dysglycemia

	Yes
	No
	I’m waiting for additional clinical trial results